Encoded Therapeutics

Encoded Therapeutics has raised $275 million in Series F financing to advance ETX101 through pivotal development for Dravet syndrome and expand its precision genetic medicines pipeline for neurological disorders.

Encoded Therapeutics' lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.

- Co led by GV and another healthcare fund, with participation from new and existing investors - - Funds ETX101 pivotal and expansion studies in Dravet syndrome alongside commercial scale-up of internal GMP manufacturing facility - - Positions ETX301 for

- Substantial seizure frequency reductions sustained through 52 weeks following ETX101 administration - - Cognitive trajectories of children treated before two years of age continue to diverge from Dravet natural history with up to 76 weeks of observation

SOUTH SAN FRANCISCO, Calif., September 08, 2026--Encoded Therapeutics Presents Updated Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the European Epilepsy Congress.

- ETX101 is an AAV9-based gene regulation therapy being developed as a one-time, disease-modifying treatment for SCN1A+ Dravet syndrome - - New Phase 1/2 data build on previously reported findings demonstrating substantial seizure reductions and neurodeve

- ETX101 demonstrated robust and durable seizure reductions through 52 weeks after a single dose - - Clinically-meaningful improvements in multiple adaptive behavior domains were observed, demonstrating measurable gains in daily functioning - - ETX101 dem

- NociPro enables highly selective nociceptor targeting and potent NaV1.7 knockdown in rodents and non-human primates, supporting development candidate ETX301 for post amputation neuroma pain - - Intravenous AAV-miRNA approach for Angelman syndrome is wel